Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study.

@article{Leiter2007EfficacyAS,
  title={Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study.},
  author={Lawrence A Leiter and Robert S Rosenson and Evan Stein and John P D Reckless and K L Schulte and Margo M Schleman and Paul Miller and Michael Ian Palmer and Froukje FM Sosef},
  journal={Atherosclerosis},
  year={2007},
  volume={194 2},
  pages={e154-64}
}
POLARIS investigated the efficacy and safety of rosuvastatin 40 mg and atorvastatin 80 mg in high-risk patients with hypercholesterolemia. Patients (n=871) were randomized to rosuvastatin 40 mg/day or atorvastatin 80 mg/day for 26 weeks. The primary endpoint was percentage change in LDL-C levels at 8 weeks. Secondary assessments included safety and tolerability, NCEP ATP III LDL-C goal achievement, change in other lipids and lipoproteins at 8 and 26 weeks, and health economics. Mean LDL-C… CONTINUE READING